Analyzing iCoreConnect (NASDAQ:ICCT) and Smead Value C (NASDAQ:SVFCX)

Earnings and Valuation

This table compares iCoreConnect and Smead Value C”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iCoreConnect	$11.05 million	0.00	-$15.55 million	($44.40)	0.00
Smead Value C	N/A	N/A	-$6.48 million	N/A	N/A

Smead Value C has lower revenue, but higher earnings than iCoreConnect.

Profitability

This table compares iCoreConnect and Smead Value C’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iCoreConnect	-263.12%	-1,451.73%	-171.32%
Smead Value C	N/A	N/A	-17.75%

Insider & Institutional Ownership

13.4% of iCoreConnect shares are held by institutional investors. Comparatively, 60.2% of Smead Value C shares are held by institutional investors. 59.4% of iCoreConnect shares are held by company insiders. Comparatively, 10.3% of Smead Value C shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

iCoreConnect has a beta of 33.29, indicating that its stock price is 3,229% more volatile than the S&P 500. Comparatively, Smead Value C has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500.

Summary

Smead Value C beats iCoreConnect on 5 of the 8 factors compared between the two stocks.

About iCoreConnect

iCoreConnect Inc., a cloud-based software and technology company, provides Health Insurance Portability and Accountability Act (HIPAA) compliant cloud-based software as a service (SaaS) in the United States. The company’s products include iCoreRx, a HIPAA compliant electronic prescription software; iCorePDMP, a solution that checks the patient’s Prescription Drug Monitoring Program (PDMP) history before prescribing controlled substances; iCoreVerify and iCoreVerify+, a HIPAA compliant SaaS solution that automatically retrieves a patients insurance eligibility breakdown to verify their benefits in advance of their appointment and on-demand; iCoreHuddle and iCoreHuddle+, a tool to instantly reveal the revenue potential of each patient; and iCoreCodeGenius, a medical coding reference SaaS solution. It also offers iCoreExchange, a SaaS email solution that allows doctors to send and receive secure email with attachments to and from other healthcare professionals; iCoreCloud, ability to backup their on-premise servers and computers to the cloud; iCoreClaims, for processing and managing claims submitted by policyholders or dental care providers; iCorePay, a patient payment processing solutions for payment and revenue cycle tracking; iCoreSecure, secure SaaS solution that solves privacy concerns in the insurance, real estate, financial and many other industry sectors; and iCoreIT, an IT managed services. The company was formerly known as iMedicor, Inc. and changed its name to iCoreConnect Inc. in June 2017. iCoreConnect Inc. was founded in 1992 and is headquartered in Ocoee, Florida.

About Smead Value C

SVF Investment Corp. 3 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was formerly known as SVF Investment III Corp. and changed its name to SVF Investment Corp. 3 in January 2021. SVF Investment Corp. 3 was incorporated in 2020 and is based in San Carlos, California.